Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.

Details

Serval ID
serval:BIB_8E270F9DEDE8
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
Journal
NPJ vaccines
Author(s)
Tanyi J.L., Chiang C.L., Chiffelle J., Thierry A.C., Baumgartener P., Huber F., Goepfert C., Tarussio D., Tissot S., Torigian D.A., Nisenbaum H.L., Stevenson B.J., Guiren H.F., Ahmed R., Huguenin-Bergenat A.L., Zsiros E., Bassani-Sternberg M., Mick R., Powell D.J., Coukos G., Harari A., Kandalaft L.E.
ISSN
2059-0105 (Electronic)
ISSN-L
2059-0105
Publication state
Published
Issued date
15/03/2021
Peer-reviewed
Oui
Volume
6
Number
1
Pages
36
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
T cells are important for controlling ovarian cancer (OC). We previously demonstrated that combinatorial use of a personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide (Cy) elicited neoantigen-specific T cells and prolonged OC survival. Here, we hypothesize that adding acetylsalicylic acid (ASA) and low-dose interleukin (IL)-2 would increase the vaccine efficacy in a recurrent advanced OC phase I trial (NCT01132014). By adding ASA and low-dose IL-2 to the OCDC-Bev-Cy combinatorial regimen, we elicited vaccine-specific T-cell responses that positively correlated with patients' prolonged time-to-progression and overall survival. In the ID8 ovarian model, animals receiving the same regimen showed prolonged survival, increased tumor-infiltrating perforin-producing T cells, increased neoantigen-specific CD8 <sup>+</sup> T cells, and reduced endothelial Fas ligand expression and tumor-infiltrating T-regulatory cells. This combinatorial strategy was efficacious and also highlighted the predictive value of the ID8 model for future ovarian trial development.
Pubmed
Web of science
Open Access
Yes
Create date
27/03/2021 16:33
Last modification date
08/05/2021 6:32
Usage data